{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:06:34Z","timestamp":1779210394393,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860653"],"award-info":[{"award-number":["81860653"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["(2019) 1462"],"award-info":[{"award-number":["(2019) 1462"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.biopha.2020.110322","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T12:19:38Z","timestamp":1591273178000},"page":"110322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549\/DDP cells"],"prefix":"10.1016","volume":"128","author":[{"given":"Xiao-Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Wu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hong","family":"L\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9916-0415","authenticated-orcid":false,"given":"Tie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2020.110322_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/acsinfecdis.7b00105","article-title":"Marine mammal microbiota yields novel antibiotic with potent activity against clostridium difficile","volume":"4","author":"Ochoa","year":"2018","journal-title":"ACS Infect. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2020.110322_bib0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/ja.2015.143","article-title":"AN483, a new anti-MRSA compound from Streptomyces sp","volume":"69","author":"Kwon","year":"2016","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"2","key":"10.1016\/j.biopha.2020.110322_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/molecules22020251","article-title":"Zunyimycins B and C, new chloroanthrabenzoxocinones antibiotics against methicillin-resistant Staphylococcus aureus and enterococci from Streptomyces sp. FJS31-2","volume":"22","author":"Lu","year":"2017","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.biopha.2020.110322_bib0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/molecules21060711","article-title":"Molecular genetic characterization of an anthrabenzoxocinones gene cluster in Streptomyces sp. FJS31-2 for the biosynthesis of BE-24566B and zunyimycin ale","volume":"21","author":"Lu","year":"2016","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.biopha.2020.110322_bib0025","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7164\/antibiotics.45.659","article-title":"C-13 beta-acyloxymilbemycins, a new family of macrolides. Discovery, structural determination and biological properties","volume":"45","author":"Haxell","year":"1992","journal-title":"J. Antibiot."},{"issue":"35","key":"10.1016\/j.biopha.2020.110322_bib0030","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/chin.199635236","article-title":"Further novel milbemycin antibiotics from Streptomyces sp. E225. Fermentation, isolation and structure elucidation","volume":"27","author":"Baker","year":"1996","journal-title":"Cheminform"},{"issue":"3","key":"10.1016\/j.biopha.2020.110322_bib0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ja.2016.130","article-title":"Isolation and identification of new macrocyclic lactones from a genetically engineered strain Streptomyces bingchenggensis BCJ60","volume":"70","author":"Li","year":"2017","journal-title":"J. Antibiot."},{"issue":"5","key":"10.1016\/j.biopha.2020.110322_bib0040","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1021\/jf902496d","article-title":"Isolation and identification of novel macrocyclic lactones from Streptomyces avermitilis NEAU1069 with acaricidal and nematocidal activity","volume":"58","author":"Xiang-Jing","year":"2010","journal-title":"J. Agric. Food Chem."},{"issue":"10","key":"10.1016\/j.biopha.2020.110322_bib0045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/ja.2009.78","article-title":"New beta-class milbemycin compound from Streptomyces avermitilis NEAU1069: fermentation, isolation and structure elucidation","volume":"62","author":"Ming","year":"2009","journal-title":"J. Antibiot."},{"issue":"50","key":"10.1016\/j.biopha.2020.110322_bib0050","first-page":"351","article-title":"Two new \u03b2-Class milbemycins from Streptomyces bingchenggensis: fermentation, isolation, structure elucidation and biological properties","volume":"38","author":"Xiang","year":"2010","journal-title":"Cheminform"},{"key":"10.1016\/j.biopha.2020.110322_bib0055","series-title":"Two New Sixteen-Membered Macrolides from the Genetically Engineered Strain Streptomyces avermitilis","first-page":"1","author":"Zhang","year":"2019"},{"issue":"10","key":"10.1016\/j.biopha.2020.110322_bib0060","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/0091270003257456","article-title":"The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans","volume":"43","author":"Cotreau","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110322_bib0065","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1017\/S0031182005008218","article-title":"Glutamate-gated chloride channels and the mode of action of the avermectin\/milbemycin anthelmintics","volume":"131","author":"Wolstenholme","year":"2005","journal-title":"Parasitology"},{"issue":"5","key":"10.1016\/j.biopha.2020.110322_bib0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2885.1996.tb00062.x","article-title":"Avermectins and milbemycins","volume":"19","author":"McKellar","year":"1996","journal-title":"J. Vet. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2020.110322_bib0075","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1016\/j.bmc.2009.01.046","article-title":"Natural products in crop protection","volume":"17","author":"Dayan","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2020.110322_bib0080","first-page":"1293","article-title":"Toxicity and adverse effects of macrocyclic lactones on dung beetles: a review","volume":"89","author":"Perez-Cogollo","year":"2018","journal-title":"Rev. Mex. Biodivers."},{"key":"10.1016\/j.biopha.2020.110322_bib0085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vetpar.2018.10.010","article-title":"The efficacy of a novel topical formulation of selamectin plus sarolaner (Revolution (R) Plus\/Stronghold (R) Plus) in preventing the development of Dirofilaria immitis in cats","volume":"270","author":"McTier","year":"2019","journal-title":"Vet. Parasitol."},{"issue":"6","key":"10.1016\/j.biopha.2020.110322_bib0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cvsm.2018.07.002","article-title":"Toxicology of avermectins and milbemycins (Macrocyclic lactones) and the role of P-glycoprotein in dogs and cats","volume":"48","author":"Merola","year":"2018","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"issue":"4613","key":"10.1016\/j.biopha.2020.110322_bib0095","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.6308762","article-title":"Ivermectin: a potent new antiparasitic agent","volume":"221","author":"Campbell","year":"1983","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2020.110322_bib0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0733-8635(02)00095-5","article-title":"Ivermectin","volume":"21","author":"Elgart","year":"2003","journal-title":"Dermatol. Clin."},{"issue":"3","key":"10.1016\/j.biopha.2020.110322_bib0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1211\/jpp.62.03.0016","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin","volume":"62","author":"Aili","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2020.110322_bib0110","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.tiv.2010.07.020","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7\/adr) cells","volume":"24","author":"Xiang","year":"2010","journal-title":"Toxicol. In Vitro"},{"issue":"2","key":"10.1016\/j.biopha.2020.110322_bib0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2011.03.023","article-title":"Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7\/adr cells in vitro","volume":"659","author":"Gao","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2020.110322_bib0120","first-page":"1348","article-title":"Moxidectin inhibits glioma cell viability by inducing G0\/G1 cell cycle arrest and apoptosis","volume":"40","author":"Song","year":"2018","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2020.110322_bib0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccell.2018.07.010","article-title":"Pulling a MAST1 on cisplatin resistance","volume":"34","author":"Jaykumar","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2020.110322_bib0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccell.2018.06.012","article-title":"MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-Independent MEK activation","volume":"34","author":"Jin","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2020.110322_bib0135","first-page":"4327","article-title":"Antitumor effects of tubeimoside-1 in NCI-H1299 cells are mediated by microRNA-126-5p-induced inactivation of VEGF-A\/VEGFR-2\/ERK signaling pathway","volume":"17","author":"Shi","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"12","key":"10.1016\/j.biopha.2020.110322_bib0140","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/bjo.2004.047928","article-title":"Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma","volume":"88","author":"Krishnakumar","year":"2004","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110322_bib0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","article-title":"Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs","volume":"11","author":"Krishna","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2020.110322_bib0150","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.biopha.2020.110322_bib0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2020.110322_bib0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1590\/S1984-82502012000300002","article-title":"Overview of P-glycoprotein inhibitors: a rational outlook","volume":"48","author":"Srivalli","year":"2012","journal-title":"Braz. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2020.110322_bib0165","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/0929867033368484","article-title":"Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways","volume":"10","author":"Fuertesa","year":"2003","journal-title":"Curr. Med. Chem."},{"issue":"323","key":"10.1016\/j.biopha.2020.110322_bib0170","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biopha.2020.110322_bib0175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001622-200011000-00007","article-title":"Lung resistance-related protein\/major vault protein and vaults in multidrug-resistant cancer","volume":"12","author":"Scheffer","year":"2000","journal-title":"Curr. Opin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110322_bib0180","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/(SICI)1097-0215(19960117)65:2<230::AID-IJC17>3.0.CO;2-H","article-title":"Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines","volume":"65","author":"Izquierdo","year":"1996","journal-title":"Int. J. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030514X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030514X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:01Z","timestamp":1777688881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222030514X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":36,"alternative-id":["S075333222030514X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110322","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549\/DDP cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110322"}}